Theialife | Myopia - World's First Clinical Phase-III Ready Oral Therapeutic For Paediatric Myopia Progression Control

SIGHT
FOR
LIFE

Transforming lives by developing innovative treatments for ocular diseases that helps restore sight for life

2.2 B

people with vision impairement

2.64 B

people who have myopia

460 M

people with high myopia

IMPACT WITH NUMBERS

Theialife's commitment to innovation is reflected in our impressive metrics, demonstrating our impact in ophthalmology

Our lead asset, 7MX is poised to become the first oral therapy for early-onset-pediatric-myopia and is set to enter global Phase III clinical trials in 2025.

JOIN US

Building the future
of ophthalmology

We are on a mission to tackle some of the world's biggest health challenges, trying to find solutions where none exist. At Theialife, we seek partners who want to push back the boundaries of innovation on behalf of patients.

LET'S WORK TOGETHER

This molecular platform has a innovative approach to potentially address neovascular age related macular degeneration & Pterygium.

XP

Our lead molecular platform that has the capability to address various indications including Pediatric Myopia, Dry-Eye Disease & UV-B Cataract.

ND10

Using an innovative approach to drug discovery, this molecular platform is uniquely positioned to address Keratoconus & Corneal blindness.

rHCT3

Stumbling-into-the-brave-new-world-of-gene-editing-_bfb3b5b9-a0a9-46eb-9230-9754e9bce622-2

2o years of real-world clinical usage in Denmark, with nil reported adverse effects.

PROPRIETARY OPTHAMOLOGY PLATFORM

An innovative platform that addresses various ophthalmology unmet needs using novel molecules.

HOW IT WORKS

Its unique mechanism of action is a non-selective antagonist of the adenosine receptors, designed to limit the progression of myopia.

ND10 increases the bio-mechanical strength of the sclera and prevents eye elongation to inhibit myopia progression.

LEARN MORE

World's First Clinical Phase-3 Ready Oral Therapeutic For Paediatric Myopia

Myopia is when the eye grows too long and causes blurred vision. Commonly referred to as a short-sightedness which causes blurred distant vision. High Myopia (defined as < -6 diopters) is caused by excess elongation of the eye.

LEARN MORE

ESG

Daily disposable contact lenses generate approx. 1 KG of plastic waste per year per user

150 Billion contact lenses produced annually

4 Million (approx.) children using contact lenses to treat myopia

VS.

SUSTAINABLE VISIONARY SCIENCE

1 oral tablet of Theialife's drug produced through fermentation using renewable water sources.

0.1 kg CO2 per tablet.

MEET US AT .

ABOUT

Theialife is a virtual late-clinical stage novel ophthalmology drug company founded on an unyielding commitment to develop innovative breakthrough drug therapies for ophthalmological applications that have unmatched potential to advance the existing standard of care to prevent sight deterioration, restore patient vision and enrich lives.

NOVEL PIPELINE

We have a portfolio of first-in-class molecules that address large-unmet vision-threatening retinal diseases that can lead to further complications, like retinal detachment or blindness.

MYOPIA, THE SILENT EPIDEMIC

Our lead asset, ND10 is poised to become the first oral therapy for early-onset-pedriatric myopia and is set to enter global Phase III clinical trials in 2025.20 Years of real-world clinical usage in Denmark, with nil reported adverse effects.

SIGHT FOR LIFE